In a bubbly year for the biotech sector, these five stocks stand out over the rest -- some may surprise you.
This sector has been back in vogue, but investors could miss out on further upside without careful stock selection.
These generic biologic drugs will get a big boost from Obamacare.
This speculative drug stock is targeting the growing global problem of hospital-based infections.
Great strides are being made at these off-the-radar drug development companies. Here are 3 emerging players to watch.
Big pharma is buying back shares, and these two companies have exceptional potential.
Phillip Frost backs SafeStitch and Warren Buffett holds DaVita.
VIDEO ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
While the former looks to expand its snack and soda exposure, the latter struggles to stabilize management.
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
MONEY & POLITICS
Breaking up big banks is an untested solution to the too big to fail problem that attempts to isolate and dismantle large, troubled institutions while protecting the rest of the economy.
You may never get back the life you had before, but here are ways to improve your retirement prospects.
Wealthy Americans contribute most of the levies collected from federal personal income. But that's not the whole story.